Vericel to Report Fourth-Quarter 2018 Financial Results on February 26, 2019
13 February 2019 - 12:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell
therapies for the sports medicine and severe burn care markets,
today announced the following webcast and conference call to
discuss its fourth-quarter 2018 financial results and business
highlights.
What: |
|
Vericel Corporation
Fourth-Quarter 2018 Earnings Call |
|
|
|
When: |
|
Tuesday, February 26, 2019
at 8:30am (EDT) |
|
|
|
Where: |
|
http://investors.vcel.com/events-presentations |
|
|
|
How: |
|
The conference call will
be available live in the Investors section of the Vericel website
at http://investors.vcel.com/events-presentations. Please access
the site at least 15 minutes prior to the scheduled start time in
order to download the required audio software if
necessary. |
To participate in the live call by telephone,
please call (877) 312-5881 and reference Vericel Corporation
fourth-quarter 2018 earnings call. If calling from outside the
U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events-presentations
until February 26, 2020. A replay of the call will also be
available until 11:15am (EDT) on March 3, 2019 by calling (855)
859-2056, or from outside the U.S. (404) 537-3406. The conference
ID is 3485006.
About Vericel CorporationVericel is a leader in
advanced cell therapies for the sports medicine and severe burn
care markets. The company markets two cell therapy products in the
United States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. For more information, please visit the
company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. © 2019 Vericel Corporation. All rights reserved.
Global Media Contacts:David SchullRusso
Partners LLCDavid.schull@russopartnersllc.com +1 212-845-4271
(office)+1 858-717-2310 (mobile)
Karen ChaseRusso Partners LLCKaren.chase@russopartnersllc.com+1
646-942-5627 (office)+1 917-547-0434 (mobile)
Investor Contacts: Chad RubinSolebury
Troutcrubin@troutgroup.com+1 (646) 378-2947
Lee SternSolebury Troutlstern@troutgroup.com+1 (646)
378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024